Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Zenarestat

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

FR 74366

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats
The dorsal root ganglia (DRG) have been identified as the target tissue in diabetic somatosensory neuropathy. It has been… Expand
Is this relevant?
2006
2006
Value of repeated measures of nerve conduction and quantitative sensory testing in a diabetic neuropathy trial.
Conduct of a large, multicenter trial of the aldose reductase inhibitor zenarestat provided data on the reproducibility of… Expand
Is this relevant?
2004
2004
Natural progression of diabetic peripheral neuropathy in the Zenarestat study population.
OBJECTIVE The aim of this study was to report the baseline and natural progression of diabetic peripheral neuropathy over 12… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2003
2003
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.
Aldose reductase (ALR2) has been implicated in the etiology of diabetic complications, including blindness. Because of the… Expand
  • figure 3
  • figure 1
  • figure 2
  • table 1
  • figure 4
Is this relevant?
2002
2002
The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat.
The crystal structure of the complex of human recombinant aldose reductase (AR) with zenarestat, one of its potent inhibitors… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2002
2002
Gender Difference in the Urinary Excretion of Organic Anions in Rats
This study was aimed at clarifying the gender differences in the urinary excretion of organic anions and the gene expression of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
2001
2001
Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat
The effects of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow (NBF) were explored in streptozotocin-induced… Expand
Is this relevant?
2000
2000
The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
We studied the effects of zenarestat, an aldose reductase inhibitor (ARI), on peripheral neuropathy in Zucker diabetic fatty (ZDF… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
Objective: To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and… Expand
  • figure 1
  • figure 2
  • table 3
  • table 4
  • figure 3
Is this relevant?
1991
1991
Sex differences in excretion of zenarestat in rat.
1. Rat shows a marked sex difference in the excretion of 14C-zenarestat: only 1% of the dose was excreted in the urine of males… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE